Methods of enhancing diversity of hla haplotype expression in tumors to broaden tumor cell susceptibility to tcr-t therapy
AssigneesT-Cure Bioscience, Inc., Genvira Biosciences, Inc.
InventorsGordon PARRY, Lijuan FU, Gang ZENG, Nicholas DAVIS, Erika Von Euw, Jiahu Wang
Life of this patent
Estimating the term…
Abstract
The present invention provides methods for increasing the sensitivity of tumor cells to a TCR-engineered T cells (TCR-T) therapy comprising genetically modifying the tumor cells to express an haplotype, for example an HLA haplotype, different from the haplotype endogenous to the tumor cells.
Claims32
A method for increasing/upregulating the sensitivity of a population of tumor cells to a TCR-engineered T cell (TCR-T) therapy, the method comprising genetically modifying the population of tumor cells to express a tumor haplotype different from the tumor haplotype endogenous to the population of tumor cells.
-5. (canceled)
A method for increasing the sensitivity of a tumor cell to a TCR-engineered T cell (TCR-T) therapy comprising:
- a) determining the tumor haplotype of the population of tumor cells;
- b) contacting the population of tumor cells with a nucleic acid encoding a tumor haplotype different from the tumor haplotype endogenous to the tumor cells, wherein the tumor haplotype different from the tumor haplotype endogenous to the tumor cells is expressed, and wherein the population of tumor cells exhibit increased sensitivity to a TCR-T therapy.
-10. (canceled)
-21. (canceled)
-30. (canceled)
-37. (canceled)
-42. (canceled)
-45. (canceled)
-53. (canceled)
-61. (canceled)
-71. (canceled)
-75. (canceled)
-83. (canceled)
A peptide comprising the amino acid sequence NTDNNLAVY (SEQ ID NO:11), ATFLGSLTWK (SEQ ID NO:22), or SLLMWITQC (SEQ ID NO:33).
-87. (canceled)
Dependencies are inferred from the claim text.